Ocular Therapeutix公司 OCUL 深 滬
等待開盤 10-02 09:30:00 美东时间
11.04
-0.650
-5.56%
華盛通- 最 高12.37
- 今 開12.05
- 成交量 888.57万股
- 最 低 10.9447
- 昨 收 11.69
- 總市值 17.55亿
- 52周最高 13.85
- 市盈率 靜 --
- 換手率 5.59%
- 52周最低 5.785
- 委 比 -13.46%
- 總股本 1.59亿
- 歷史最高 44.19
- 量 比 2.73
- 振 幅 12.19%
- 歷史最低 1.995
- 每 手 1
- 風險率 2.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
今天 15:08
Ocular Therapeutix prices $475M stock offering
Ocular Therapeutix (NASDAQ:OCUL) has priced an offering of 37.9M shares at $12.53 each, aiming to raise gross proceeds of around $475.0 million. The offering is expected to close on or about October 1...
09-30 19:19
Ocular Therapeutix Updates on AXPAXLI Clinical Trials
The latest update is out from Ocular Therapeutix ( ($OCUL) ). On September 30, ...
09-30 18:58
Ocular Therapeutix Showcases Progress On New Eye Drug That Could Change Treatment For Vision Loss
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the retina experience, will host an Investor Day today where it will highlight outstanding progress in
09-30 18:22
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
Ocular Therapeutix, Inc. announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at $12.53 per share, raising approximately $475 million in gross proceeds. The offering is expected to close on October 1, 2025, subject to customary closing conditions. The company plans to use the net proceeds for its clinical trials and infrastructure improvements. BofA Securities, TD Cowen, and Piper Sandler & Co. are acting as ...
09-30 11:08
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
Ocular Therapeutix will host an Investor Day to discuss progress in their wet AMD program, AXPAXLI's potential for a superiority label over aflibercept, and plans for NPDR trials. Key highlights include the SOL-1 Phase 3 trial showing exceptional patient retention and safety, SOL-R non-inferiority trial targeting 1H 2027 data, and HELIOS-2/3 trials evaluating AXPAXLI in NPDR with a novel ordinal DRSS endpoint. The event also previews the SOL-X op...
09-30 10:21
Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities
A notification regarding trades executed by a PDMR (Person Discharging Managerial Responsibilities) under a 10b5-1 trading plan, in compliance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, has been issued.
09-26 20:05
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Chardan Capital Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $21
Chardan Capital analyst Daniil Gataulin initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $21.
09-15 18:21
Ocular Therapeutix™ to Host Investor Day on September 30, 2025
Ocular Therapeutix, Inc. invites investors and media to an Investor Day on September 30, 2025, in New York City. The event will feature presentations by senior leadership, discussions with global retina experts, and a Q&A session. Key topics include the AXPAXLI™ wet AMD registrational program, clinical strategies for NPDR and DME, and global commercial opportunities. Featured experts are Dr. Arshad M. Khanani, Professor Adnan Tufail, Dr. Eleonora...
09-08 11:00
